Zidovudine (AZT) usage is an even more dramatically uneven health care option.
At several thousand dollars a year, middle-income people have been brought to their financial knees by the burden of its cost.
Even the well-insured and/or very affluent are stunned.
Inclusion of AZT as a Medicaid option has been met by a number of states with reluctance, or horribly, with refusal until recently: as recently as July, 1989 there are still two states in this wealthy land where AZT simply was not available if one was poor.
Mots-clés Pascal : Virose, Infection, Zidovudine, Antiviral, Programme sanitaire, Statut socioéconomique, Accessibilité, Financement, Immunodéficit acquis syndrome, Hémopathie, Immunopathologie, Maladie sexuellement transmissible, Traitement
Mots-clés Pascal anglais : Viral disease, Infection, Antiviral, Sanitary program, Socioeconomic status, Accessibility, Financing, AIDS, Hemopathy, Immunopathology, Sexually transmitted disease, Treatment
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 91-0197536
Code Inist : 002B06D01. Création : 199406.